HK1079220A1 - Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases cd83 - Google Patents

Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases cd83

Info

Publication number
HK1079220A1
HK1079220A1 HK05111319.6A HK05111319A HK1079220A1 HK 1079220 A1 HK1079220 A1 HK 1079220A1 HK 05111319 A HK05111319 A HK 05111319A HK 1079220 A1 HK1079220 A1 HK 1079220A1
Authority
HK
Hong Kong
Prior art keywords
diseases
prevention
treatment
nucleic acids
acids encoding
Prior art date
Application number
HK05111319.6A
Other languages
English (en)
Chinese (zh)
Inventor
Alexander Steinkasserer
Matthias Lechmann
Elisabeth Zinser
Original Assignee
Argos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argos Therapeutics Inc filed Critical Argos Therapeutics Inc
Publication of HK1079220A1 publication Critical patent/HK1079220A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
HK05111319.6A 2002-11-19 2005-12-09 Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases cd83 HK1079220A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02025851A EP1422241A1 (fr) 2002-11-19 2002-11-19 Utilisation des formes solubles des CD83 et acides nucleiques les codant dans letraitement et la prevention des maladies
PCT/EP2003/012941 WO2004046182A2 (fr) 2002-11-19 2003-11-19 Utilisation de formes solubles de cd83 et d'acides nucleiques codant pour cd83 afin de traiter ou de prevenir des maladies

Publications (1)

Publication Number Publication Date
HK1079220A1 true HK1079220A1 (en) 2006-03-31

Family

ID=32187165

Family Applications (2)

Application Number Title Priority Date Filing Date
HK05111319.6A HK1079220A1 (en) 2002-11-19 2005-12-09 Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases cd83
HK14107931.1A HK1194400A1 (zh) 2002-11-19 2014-08-04 編碼 可溶形式的核酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK14107931.1A HK1194400A1 (zh) 2002-11-19 2014-08-04 編碼 可溶形式的核酸

Country Status (10)

Country Link
US (3) US7893200B2 (fr)
EP (5) EP1422241A1 (fr)
JP (3) JP4740595B2 (fr)
AU (1) AU2003292045A1 (fr)
CA (2) CA2847795C (fr)
DK (1) DK1562985T3 (fr)
ES (2) ES2413631T3 (fr)
HK (2) HK1079220A1 (fr)
SI (1) SI1562985T1 (fr)
WO (1) WO2004046182A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1422241A1 (fr) 2002-11-19 2004-05-26 Alexander Steinkasserer Utilisation des formes solubles des CD83 et acides nucleiques les codant dans letraitement et la prevention des maladies
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
WO2008024242A2 (fr) 2006-08-18 2008-02-28 Argos Therapeutics, Inc. Utilisation de cd83 dans des polythérapies
WO2009108341A1 (fr) 2008-02-28 2009-09-03 Argos Therapeutics, Inc. Expression transitoire de polypeptides immunomodulateurs dans la prévention et le traitement des maladies auto-immunes, l’allergie et le rejet de greffe
CN102036690B (zh) * 2008-05-23 2013-11-06 阿哥斯医疗公司 新型可溶性cd83多肽、制剂及使用方法
EP3275898B1 (fr) * 2009-11-05 2024-06-05 Osaka University Agent thérapeutique pour des maladies auto-immunes ou une allergie et procédé de criblage pour l'agent thérapeutique
CN109369807B (zh) * 2015-01-27 2021-07-27 中国科学技术大学先进技术研究院 抗人cd83单克隆抗体及其制备、鉴定和应用
US10688178B2 (en) 2015-06-30 2020-06-23 Osaka University AntiPlexin A1 agonist antibody
US20190315878A1 (en) 2016-11-07 2019-10-17 Argos Therapeutics Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
RU2729079C1 (ru) 2017-01-31 2020-08-04 Кимберли-Кларк Ворлдвайд, Инк. Антибактериальная композиция, содержащая сложный эфир бензойной кислоты, и способы подавления бактериального роста посредством ее применения
EP3895723A1 (fr) 2020-04-16 2021-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Scd83 pour la cicatrisation des plaies, la croissance des cheveux et les soins de la peau et des cheveux

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316920A (en) * 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
US5710262A (en) 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
AU2273397A (en) * 1996-02-15 1997-09-02 Immunex Corporation Methods and compositions for modulating an immune response
ATE324443T1 (de) 1997-08-26 2006-05-15 Zymogenetics Inc Für adipozyten spezifische protein homologe
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
GB2370273A (en) 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
AU2002240734A1 (en) * 2001-10-18 2003-04-28 Zlatko Ademovic Repetitive motifs from salivary proline rich proteins, mucin and collagen
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
WO2003045318A2 (fr) 2001-11-21 2003-06-05 Celltech R & D, Inc. Manipulation de taux de cytokine au moyen de produits de gene cd83
US6652537B2 (en) 2001-12-12 2003-11-25 C. R. Bard, Inc. Articulating stone basket
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
AU2002950779A0 (en) 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
JP2006503110A (ja) * 2002-10-09 2006-01-26 トーラーレックス， インク． エフェクタｔ細胞または制御性ｔ細胞に選択的に結合する分子およびその使用方法
EP1422241A1 (fr) 2002-11-19 2004-05-26 Alexander Steinkasserer Utilisation des formes solubles des CD83 et acides nucleiques les codant dans letraitement et la prevention des maladies
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
CN102036690B (zh) 2008-05-23 2013-11-06 阿哥斯医疗公司 新型可溶性cd83多肽、制剂及使用方法

Also Published As

Publication number Publication date
US9732140B2 (en) 2017-08-15
CA2507373C (fr) 2014-06-10
JP5557765B2 (ja) 2014-07-23
AU2003292045A8 (en) 2004-06-15
EP2345670A1 (fr) 2011-07-20
JP2014195455A (ja) 2014-10-16
US7893200B2 (en) 2011-02-22
EP2345670B1 (fr) 2013-03-20
JP2011144177A (ja) 2011-07-28
US20150065684A1 (en) 2015-03-05
ES2534308T3 (es) 2015-04-21
JP5878584B2 (ja) 2016-03-08
DK1562985T3 (da) 2015-04-13
SI1562985T1 (sl) 2015-05-29
EP3031824A1 (fr) 2016-06-15
CA2507373A1 (fr) 2004-06-03
US8759505B2 (en) 2014-06-24
CA2847795A1 (fr) 2004-06-03
EP1562985A2 (fr) 2005-08-17
CA2847795C (fr) 2018-05-01
HK1194400A1 (zh) 2014-10-17
EP2692733A1 (fr) 2014-02-05
WO2004046182A2 (fr) 2004-06-03
US20120015890A1 (en) 2012-01-19
EP1422241A1 (fr) 2004-05-26
JP4740595B2 (ja) 2011-08-03
ES2413631T3 (es) 2013-07-17
AU2003292045A1 (en) 2004-06-15
EP2692733B1 (fr) 2015-11-18
US20070167607A1 (en) 2007-07-19
WO2004046182A3 (fr) 2004-10-14
EP1562985B1 (fr) 2015-01-07
JP2006523432A (ja) 2006-10-19

Similar Documents

Publication Publication Date Title
HK1079220A1 (en) Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases cd83
EP1575480A4 (fr) Compositions et methodes de traitement de maladies relatives au systeme immunitaire
EP1578367A4 (fr) Compositions et methodes pour le traitement de maladies liees au systeme immunitaire
EP1572116A4 (fr) Compositions et procedes destines au traitement de maladies de nature immune
EP1576137A4 (fr) Compositions et methodes de traitement de maladies liees au systeme immunitaire
EP1416961A4 (fr) Composition et procede pour le traitement d'une maladie
HRP20040906B1 (en) Bisphosphonic acid for the treatment and prevention of ostreoporosis
EP1571968A4 (fr) Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
EP1589933A4 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
SI1487541T1 (sl) Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
WO2004024097A9 (fr) Compositions et methodes de traitement de maladies de nature immune
IL165950A0 (en) Compositions and method for the diagnosis and treatment of tumor
EP1553912A4 (fr) Compositions et methodes pour le diagnostic et pour le traitement d'une tumeur
EP1578996A4 (fr) Compositions et methodes pour diagnostiquer et traiter des tumeurs
EP1560593A4 (fr) Nouvelle composition et procedes pour le traitement de maladies auto-immunes
EP1575571A4 (fr) Compositions et methodes de diagnostic et de traitement d'une tumeur
AU2003225281A8 (en) Materials and methods for prevention and treatment of rna viral diseases
AU2003299378A8 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
HRP20030609A2 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
EP1624786A4 (fr) Techniques de traitement et de prevention de maladies de conduits biologiques
EP1472273A4 (fr) Compositions et methodes de traitement de maladies d'origine immune
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2003228339A1 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
GB0201025D0 (en) The treatment of degenerative diseases
EP1572130A4 (fr) Compositions et procedes destines au traitement de maladies liees au systeme immunitaire

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20231118